<DOC>
	<DOCNO>NCT00414349</DOCNO>
	<brief_summary>The purpose study evaluate lidocaine topical treatment peripheral neuropathic pain ( stand-alone treatment combination systemic treatment )</brief_summary>
	<brief_title>Efficacy Safety Topical Versus Systemic Treatment Postherpetic Neuralgia Diabetic Polyneuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Male female subject &gt; = 18 year age Intact skin area topical treatment Creatinine clearance CLCR &gt; = 30 mL/min NRS3 &gt; 4 ( recall average pain intensity last 3 day ) Subjects DPN Controlled , treat type 1 2 diabetes mellitus glycosylated hemoglobin ( Hba1c ) &lt; = 11 % Painful , distal symmetrical , sensomotor polyneuropathy low extremity &gt; = 3 month ( knee extremity ) least 2 follow symptom present : burning , sensation , tingle prickling , numbness time time , painful heat cold sensation ( e.g . warm cold water ) Subjects PHN Subjects PHN neuropathic pain present &gt; = 3 month heal herpes zoster skin rash . Without neurolytic neurosurgical therapy condition . General Evidence history alcohol , medication drug abuse and/or dependency past 2 year , unstable psychological personality require intermittent permanent treatment . Psychiatric illness ( subject wellcontrolled depression anxiety disorder may participate take prohibited medication define ( ) , epilepsy suicide risk . Pregnant breastfeed woman Women childbearing potential sexually active without satisfactory contraception least 28 day prior enrollment , trial , 28 day followup visit . Subjects severe cardiac impairment e.g . NYHA class &gt; 3 , myocardial infarction le 6 month prior enrollment , and/or unstable angina pectoris . Subjects severe hepatic disorder and/or AST ALT &gt; = 3x upper limit normal . Subjects know suspect severe renal failure ( CLCR &lt; 30 mL/min ) . Anticipated need surgery trial , require least regional general anesthesia . Subjects undergo active treatment cancer , know infected HIV acutely intensively immunosuppressed follow transplantation . Participation another trial investigational medicinal product device parallel less 1 month entry trial , previous participation trial . Trial specific : Any concomitant use drug treatment neuropathic pain commonly use treatment neuropathic pain . Use transcutaneous electrical nerve stimulation ( TENS ) enrollment . CLCR &lt; 30 mL/min Evidence another cause pain area neuropathic pain lumbar radiculopathy , surgery trauma , restless legs syndrome , coud confound assessment selfevaluation neuropathic pain . Presence severe pain could confound assessment selfevaluation neuropathic pain . History malignancy within past 5 year ( exception basal cell carcinoma ) . Subjects PHN Active herpes zoster lesion dermatitis origin affect site PHN . Subjects neurological ablation block neurosurgical intervention control pain PHN . Subjects DPN No palpable pulse arteria dorsalis pedis foot . Clinical sign venous insufficiency and/or postthrombotic syndrome Sage III/IV ( i.e . extensive varicoses ) Ulcers low extremity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Topical analgesic</keyword>
	<keyword>Multiple dose</keyword>
</DOC>